Taldefgrobep alfa

• CAT Number: I042136
• CAS Number: 1580555-26-5
• Purity: ≥95%

Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2].
Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) has rapid plasma clearance after intravenous administration in mice, but slow absorption (Tmax=24 h) after subcutaneous administration with Cmax=15.4 mg/mL and bioavailability (F)=84%[1].

Reference

[1]. Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016 Feb;8(3):193-204.
 [Content Brief]

[2]. Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42(12).